Markers for the Early Detection of Prostate Cancer: Some Principles for Statistical Reporting and Interpretation
Menée entre 2009 et 2011 auprès de 859 hommes (âge moyen : 62 ans), cette étude évalue, par rapport au test du PSA, l'intérêt du dosage de l'antigène PCA3 dans les urines pour diagnostiquer précocement un cancer de la prostate
In the article that accompanies this editorial, Wei et al report the results of a National Cancer Institute Early Detection Research Network (EDRN) validation study of PCA3, a commercially available marker used as a reflex test in the early detection of prostate cancer. The study design followed the EDRN′s rigorous methodology, including fully blinded analysis of samples at an independent laboratory and statistical correction for overfit. The study was also well powered, with more than 800 men recruited at 11 centers. Given that typical marker studies involve novel markers, small samples (median less than 100), and little attempt to control for overfit, there is much to like about this article. The authors are to be congratulated for completing such a large and rigorous study...
Journal of Clinical Oncology , éditorial en libre accès, 2014